Prostate autoimmunity: from experimental models to clinical counterparts

References

• Nickel JC. The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Curr. Opin. Urol.16(1), 5–10 (2006).
   PubMed Web of Science ®Google Scholar
• Steiner GE, Djavan B, Kramer G et al. The picture of the prostatic lymphokine network is becoming increasingly complex. Rev. Urol.4(4), 171–177 (2002).
   PubMedGoogle Scholar
• Krieger JN, Lee SW, Jeon J et al. Epidemiology of prostatitis. Int. J. Antimicrob. Agents31(Suppl. 1), S85–S90 (2008).
   Google Scholar
• Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA282(3), 236–237 (1999).
   PubMed Web of Science ®Google Scholar
• Schaeffer AJ. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N. Engl. J. Med.355(16), 1690–1698 (2006).
   PubMedGoogle Scholar
• Roehrborn CG. Pathology of benign prostatic hyperplasia. Int. J. Impot. Res.20(Suppl. 3), S11–S18 (2008).
   PubMed Web of Science ®Google Scholar
• Whitmore WF, Gittes RF. Studies on the prostate and testis as immunologically privileged sites. Cancer Treat. Rep.61(2), 217–222 (1977).
   PubMedGoogle Scholar
• Vykhovanets EV, Resnick MI, Marengo SR. The healthy rat prostate contains high levels of natural killer-like cells and unique subsets of CD4+ helper-inducer T cells: implications for prostatitis. J. Urol.173(3), 1004–1010 (2005).
   PubMedGoogle Scholar
• Steiner G, Gessl A, Kramer G et al. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J. Urol.151(2), 480–484 (1994).
   PubMed Web of Science ®Google Scholar
• Kramer G, Steiner GE, Handisurya A et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate52(1), 43–58 (2002).
   PubMed Web of Science ®Google Scholar
• Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur. Urol.51(5), 1202–1216 (2007).
   PubMed Web of Science ®Google Scholar
• Konig JE, Senge T, Allhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate58(2), 121–129 (2004).
   PubMed Web of Science ®Google Scholar
• Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human Toll-like receptors and related genes. Biol. Pharm. Bull.28(5), 886–892 (2005).
   PubMed Web of Science ®Google Scholar
• Gatti G, Rivero V, Motrich RD, Maccioni M. Prostate epithelial cells can act as early sensors of infection by up-regulating TLR4 expression and proinflammatory mediators upon LPS stimulation. J. Leukoc. Biol.79(5), 989–998 (2006).
   PubMed Web of Science ®Google Scholar
• Penna G, Fibbi B, Amuchastegui S et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J. Immunol.182(7), 4056–4064 (2009).
   PubMed Web of Science ®Google Scholar
• Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature449(7164), 819–826 (2007).
   PubMed Web of Science ®Google Scholar
• Zisman A, Zisman E, Lindner A et al. Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia. J. Urol.154(3), 1052–1055 (1995).
   PubMed Web of Science ®Google Scholar
• Zisman A, Lindner A, Zisman E, Lindner U, Mozes E. Prostate-specific antigen induces proliferation of peripheral blood lymphocytes and cytokine secretion in benign prostate hypertrophy patients. Eur. Urol.36(3), 258–265 (1999).
   PubMedGoogle Scholar
• Dardalhon V, Korn T, Kuchroo VK, Anderson AC. Role of Th1 and Th17 cells in organ-specific autoimmunity. J. Autoimmun.31(3), 252–256 (2008).
   PubMed Web of Science ®Google Scholar
• Motrich RD, Maccioni M, Riera CM, Rivero VE. Autoimmune prostatitis: state of the art. Scand J. Immunol.66(2–3), 217–227 (2007).
   PubMedGoogle Scholar
• Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J. Urol.179(5 Suppl.), S61–S67 (2008).
   Web of Science ®Google Scholar
• Vykhovanets EV, Resnick MI, Maclennan GT, Gupta S. Experimental rodent models of prostatitis: limitations and potential. Prostate Cancer Prostatic Dis.10(1), 15–29 (2007).
   PubMedGoogle Scholar
• Liu KJ, Chatta GS, Twardzik DR et al. Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy. J. Immunol.159(1), 472–480 (1997).
   PubMedGoogle Scholar
• Penna G, Amuchastegui S, Cossetti C et al. Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse. J. Immunol.179(3), 1559–1567 (2007).
   PubMed Web of Science ®Google Scholar
• Kikutani H, Makino S. The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol.51, 285–322 (1992).
   PubMed Web of Science ®Google Scholar
• Rivero VE, Cailleau C, Depiante-Depaoli M, Riera CM, Carnaud C. Non-obese diabetic (NOD) mice are genetically susceptible to experimental autoimmune prostatitis (EAP). J. Autoimmun.11(6), 603–610 (1998).
   PubMedGoogle Scholar
• Rivero V, Carnaud C, Riera CM. Prostatein or steroid binding protein (PSBP) induces experimental autoimmune prostatitis (EAP) in NOD mice. Clin. Immunol.105(2), 176–184 (2002).
   PubMedGoogle Scholar
• Maccioni M, Rivero VE, Riera CM. Prostatein (or rat prostatic steroid binding protein) is a major autoantigen in experimental autoimmune prostatitis. Clin. Exp. Immunol.112(2), 159–165 (1998).
   PubMedGoogle Scholar
• Penna G, Amuchastegui S, Cossetti C et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J. Immunol.177(12), 8504–8511 (2006).
   PubMed Web of Science ®Google Scholar
• Taguchi O, Kojima A, Nishizuka Y. Experimental autoimmune prostatitis after neonatal thymectomy in the mouse. Clin. Exp. Immunol.60(1), 123–129 (1985).
   PubMedGoogle Scholar
• Taguchi O, Nishizuka Y. Self tolerance and localized autoimmunity. Mouse models of autoimmune disease that suggest tissue-specific suppressor T cells are involved in self tolerance. J. Exp. Med.165(1), 146–156 (1987).
   PubMed Web of Science ®Google Scholar
• Taguchi O, Kontani K, Ikeda H et al. Tissue-specific suppressor T cells involved in self-tolerance are activated extrathymically by self-antigens. Immunology82(3), 365–369 (1994).
   PubMed Web of Science ®Google Scholar
• Seethalakshmi L, Bala RS, Malhotra RK et al. 17 β-estradiol induced prostatitis in the rat is an autoimmune disease. J. Urol.156(5), 1838–1842 (1996).
   PubMedGoogle Scholar
• Harris MT, Feldberg RS, Lau KM, Lazarus NH, Cochrane DE. Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate44(1), 19–25 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson MJ, Woodson M, Wiehr C, Reddy A, Sinha AA. Matrix metalloproteinases in the pathogenesis of estradiol-induced nonbacterial prostatitis in the lateral prostate lobe of the Wistar rat. Exp. Mol. Pathol.77(1), 7–17 (2004).
   PubMed Web of Science ®Google Scholar
• Corman JM, Sercarz EE, Nanda NK. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin. Exp. Immunol.114(2), 166–172 (1998).
   PubMedGoogle Scholar
• Alexander RB, Brady F, Ponniah S. Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology50(6), 893–899 (1997).
   PubMed Web of Science ®Google Scholar
• Batstone GR, Doble A, Gaston JS. Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS). Clin. Exp. Immunol.128(2), 302–307 (2002).
   PubMed Web of Science ®Google Scholar
• Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate44(1), 49–54 (2000).
   PubMedGoogle Scholar
• Motrich RD, Maccioni M, Molina R et al. Presence of INF-γ-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin. Immunol.116(2), 149–157 (2005).
   PubMedGoogle Scholar
• Dunphy EJ, Eickhoff JC, Muller CH, Berger RE, McNeel DG. Identification of antigen-specific IgG in sera from patients with chronic prostatitis. J. Clin. Immunol.24(5), 492–502 (2004).
   PubMedGoogle Scholar
• Klyushnenkova EN, Link J, Oberle WT et al. Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostate-specific antigen. Clin. Cancer Res.11(8), 2853–2861 (2005).
   PubMedGoogle Scholar
• Klyushnenkova EN, Kouiavskaia DV, Kodak JA, Vandenbark AA, Alexander RB. Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase. Prostate67(10), 1019–1028 (2007).
   PubMedGoogle Scholar
• Kodak JA, Mann DL, Klyushnenkova EN, Alexander RB. Activation of innate immunity by prostate specific antigen (PSA). Prostate66(15), 1592–1599 (2006).
   PubMedGoogle Scholar
• Penna G, Mondaini N, Amuchastegui S et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin-8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur. Urol.51, 524–533 (2007).
   PubMed Web of Science ®Google Scholar
• Rivero VE, Motrich RD, Maccioni M, Riera CM. Autoimmune etiology in chronic prostatitis syndrome: an advance in the understanding of this pathology. Crit. Rev. Immunol.27(1), 33–46 (2007).
   PubMedGoogle Scholar
• Eriksson U, Ricci R, Hunziker L et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat. Med.9(12), 1484–1490 (2003).
   PubMed Web of Science ®Google Scholar
• Anders HJ, Vielhauer V, Eis V et al. Activation of Toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J.18(3), 534–536 (2004).
   PubMed Web of Science ®Google Scholar
• Pontari MA. Etiologic theories of chronic prostatitis/chronic pelvic pain syndrome. Curr. Urol. Rep.8(4), 307–312 (2007).
   PubMedGoogle Scholar
• Schaeffer AJ, Knauss JS, Landis JR et al. Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study. J. Urol.168(3), 1048–1053 (2002).
   PubMed Web of Science ®Google Scholar
• Tsuboi N, Nishimura T, Chen H et al. Relation of leukocytosis in prostatic fluid and inflamed prostatic tissue. J. Nippon. Med. Sch.74(3), 210–216 (2007).
   PubMedGoogle Scholar
• Nickel JC, Roehrborn CG, O’Leary MP et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur. Urol.54(6), 1379–1384 (2008).
   PubMed Web of Science ®Google Scholar
• Straub RH. The complex role of estrogens in inflammation. Endocr. Rev.28(5), 521–574 (2007).
   PubMed Web of Science ®Google Scholar
• Webber R. Benign prostatic hyperplasia. Clin. Evid.(15), 1213–1226 (2006).
   PubMedGoogle Scholar
• Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J. Urol.172(5 Pt 1), 1784–1791 (2004).
   PubMedGoogle Scholar
• Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: basic science implications. Curr. Urol. Rep.9(4), 272–278 (2008).
   PubMedGoogle Scholar
• Nickel JC. Inflammation and benign prostatic hyperplasia. Urol. Clin. North Am.35(1), 109–115; vii (2008).
   PubMed Web of Science ®Google Scholar
• Sciarra A, Mariotti G, Salciccia S et al. Prostate growth and inflammation. J. Steroid. Biochem. Mol. Biol.108(3–5), 254–260 (2008).
   PubMed Web of Science ®Google Scholar
• Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int.84(9), 976–981 (1999).
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int.97(Suppl. 2), 7–11; discussion 21–12 (2006).
   PubMed Web of Science ®Google Scholar
• Steiner GE, Stix U, Handisurya A et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab. Invest.83(8), 1131–1146 (2003).
   PubMed Web of Science ®Google Scholar
• Handisurya A, Steiner GE, Stix U et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate49(4), 251–262 (2001).
   PubMedGoogle Scholar
• Steiner GE, Newman ME, Paikl D et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate56(3), 171–182 (2003).
   PubMed Web of Science ®Google Scholar
• Prakash K, Pirozzi G, Elashoff M et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc. Natl Acad. Sci. USA99(11), 7598–7603 (2002).
   PubMedGoogle Scholar
• Crescioli C, Ferruzzi P, Caporali A et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a Phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol.150(4), 591–603 (2004).
   PubMed Web of Science ®Google Scholar
• Adorini L, Penna G, Amuchastegui S et al. Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J. Steroid Biochem. Mol. Biol.103(3–5), 689–693 (2007).
   PubMed Web of Science ®Google Scholar
• Colli E, Rigatti P, Montorsi F et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur. Urol.49(1), 82–86 (2006).
   PubMed Web of Science ®Google Scholar
• Morelli A, Vignozzi L, Filippi S et al. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate67(3), 234–247 (2007).
   PubMed Web of Science ®Google Scholar
• Bates S, Talbot M. Short course oral prednisolone therapy in chronic abacterial prostatitis and prostatodynia: case reports of three responders and one non-responder. Sex. Transm. Infect.76(5), 398–399 (2000).
   PubMedGoogle Scholar
• Nickel JC. The three As of chronic prostatitis therapy: antibiotics, α-blockers and anti-inflammatories. What is the evidence? BJU Int.94(9), 1230–1233 (2004).
   PubMedGoogle Scholar
• Dhar NB, Shoskes DA. New therapies in chronic prostatitis. Curr. Urol. Rep.8(4), 313–318 (2007).
   PubMedGoogle Scholar
• Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol.4, 404–412 (2008).
   PubMedGoogle Scholar
• Galmarini M, Riera CM, Pesoa S, Vullo C, Vottero-Cima E. Induction of humoral autoimmune response to rat male accessory glands. Medicina (B. Aires)41(3), 349–353 (1981).
   PubMedGoogle Scholar
• Pacheco-Rupil B, Depiante-Depaoli M, Casadio B. Experimental autoimmune damage to rat male accessory glands. II. T cell requirement in adoptive transfer of specific tissue damage. Am. J. Reprod. Immunol.5(1), 15–19 (1984).
   Web of Science ®Google Scholar
• Depiante-Depaoli M, Pacheco-Rupil B, Britos S, Casas A. Experimental autoimmune damage to rat male accessory glands. I. Transfer of autoimmune response by spleen cells. Am. J. Reprod. Immunol.5(1), 9–14 (1984).
   Web of Science ®Google Scholar
• Depiante-Depaoli M, Pacheco-Rupil B. Experimental autoimmunity to rat male accessory glands (MAG): circulating antibodies, immunoglobulins bound to target glands, and immunoglobulins-secreting cells. Am. J. Reprod. Immunol. Microbiol.7(1), 32–38 (1985).
   PubMedGoogle Scholar
• Casas-Ingaramo A, Depiante-Depaoli M, Pacheco-Rupil B. Activation of cytotoxic cells by syngeneic prostate antigens in experimental autoimmune vesiculo-prostatitis. Autoimmunity9(2), 151–157 (1991).
   PubMed Web of Science ®Google Scholar
• Rivero VE, Iribarren P, Riera CM. Mast cells in accessory glands of experimentally induced prostatitis in male Wistar rats. Clin. Immunol. Immunopathol.74(3), 236–242 (1995).
   PubMedGoogle Scholar
• Maccioni M, Rivero V, Riera CM. Autoantibodies against rat prostate antigens. Association of specific IGG2b and IGG2c with the DTH response. J. Autoimmun.9(4), 485–491 (1996).
   PubMedGoogle Scholar
• Galmarini M, Ferro ME, Riera CM. Delayed hypersensitivity and lesions following isoimmunization with modified rat male accessory glands: kinetics of induction. J. Reprod. Immunol.13(2), 147–157 (1988).
   PubMedGoogle Scholar
• Donadio AC, Gagliano H, Remedi MM, Nowotny E, Depiante-Depaoli M. Time-course study of cellular immune response and testosterone metabolism in an autoimmune model for chronic prostatic inflammation. J. Urol.160(4), 1546–1550 (1998).
   PubMedGoogle Scholar
• Keetch DW, Humphrey P, Ratliff TL. Development of a mouse model for nonbacterial prostatitis. J. Urol.152(1), 247–250 (1994).
   PubMedGoogle Scholar
• Correale P, Walmsley K, Nieroda C et al.in vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl Cancer Inst.89(4), 293–300 (1997).
   PubMed Web of Science ®Google Scholar
• Xue BH, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate30(2), 73–78 (1997).
   PubMed Web of Science ®Google Scholar
• Correale P, Walmsley K, Zaremba S et al. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J. Immunol.161(6), 3186–3194 (1998).
   PubMed Web of Science ®Google Scholar
• Berlyn KA, Schultes B, Leveugle B et al. Generation of CD4+ and CD8+ T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin. Immunol.101(3), 276–283 (2001).
   PubMed Web of Science ®Google Scholar
• Harada M, Kobayashi K, Matsueda S et al. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. Prostate57(2), 152–159 (2003).
   PubMed Web of Science ®Google Scholar
• Hural JA, Friedman RS, McNabb A et al. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J. Immunol.169(1), 557–565 (2002).
   PubMed Web of Science ®Google Scholar
• Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J. Immunol.159(7), 3113–3117 (1997).
   PubMed Web of Science ®Google Scholar
• McNeel DG, Nguyen LD, Disis ML. Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res.61(13), 5161–5167 (2001).
   PubMed Web of Science ®Google Scholar